Eldafashi Nardeen, Darlay Rebecca, Shukla Ruchi, McCain Misti Vanette, Watson Robyn, Liu Yang Lin, McStraw Nikki, Fathy Moustafa, Fawzy Michael Atef, Zaki Marco Y W, Daly Ann K, Maurício João P, Burt Alastair D, Haugk Beate, Cordell Heather J, Bianco Cristiana, Dufour Jean-François, Valenti Luca, Anstee Quentin M, Reeves Helen L
Translational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Biochemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Cancers (Basel). 2021 Mar 19;13(6):1412. doi: 10.3390/cancers13061412.
Obesity and non-alcoholic fatty liver disease (NAFLD) are contributing to the global rise in deaths from hepatocellular carcinoma (HCC). The pathogenesis of NAFLD-HCC is not well understood. The severity of hepatic steatosis, steatohepatitis and fibrosis are key pathogenic mechanisms, but animal studies suggest altered immune responses are also involved. Genetic studies have so far highlighted a major role of gene variants promoting fat deposition in the liver ( rs738409; rs58542926). Here, we have considered single-nucleotide polymorphisms (SNPs) in candidate immunoregulatory genes ( rs2596542; rs187115; rs7421861 and rs10204525), in 594 patients with NAFLD and 391 with NAFLD-HCC, from three European centres. Associations between age, body mass index, diabetes, cirrhosis and SNPs with HCC development were explored. and SNPs were associated with both progression to cirrhosis and NAFLD-HCC development, while SNPs were specifically associated with NAFLD-HCC risk, regardless of cirrhosis. rs7421861 was independently associated with NAFLD-HCC development, while rs10204525 acquired significance after adjusting for other risks, being most notable in the smaller numbers of women with NAFLD-HCC. The study highlights the potential impact of inter individual variation in immune tolerance induction in patients with NAFLD, both in the presence and absence of cirrhosis.
肥胖和非酒精性脂肪性肝病(NAFLD)导致全球肝细胞癌(HCC)死亡人数上升。NAFLD-HCC的发病机制尚不完全清楚。肝脂肪变性、脂肪性肝炎和纤维化的严重程度是关键的致病机制,但动物研究表明免疫反应改变也与之相关。迄今为止,基因研究突出了促进肝脏脂肪沉积的基因变异(rs738409;rs58542926)的主要作用。在此,我们研究了来自三个欧洲中心的594例NAFLD患者和391例NAFLD-HCC患者中候选免疫调节基因(rs2596542;rs187115;rs7421861和rs10204525)中的单核苷酸多态性(SNP)。探讨了年龄、体重指数、糖尿病、肝硬化和SNP与HCC发生之间的关联。某些SNP与进展为肝硬化和NAFLD-HCC的发生均相关,而其他SNP则与NAFLD-HCC风险特异性相关,无论是否存在肝硬化。rs7421861与NAFLD-HCC的发生独立相关,而rs10204525在调整其他风险后具有统计学意义,在NAFLD-HCC女性患者数量较少的情况下最为显著。该研究强调了NAFLD患者免疫耐受诱导个体差异的潜在影响,无论是否存在肝硬化。